

## Supplementary Material

### Effectiveness in real-world of once weekly semaglutide in people with type 2 diabetes glucagon-like peptide receptor agonists naïve or switchers from other glucagon-like peptide receptor agonists: results from a retrospective observational Umbria Study

Chiara Di Loreto<sup>1</sup>, Viviana Minarelli<sup>2</sup>, Giovanni Nasini<sup>3</sup>, Roberto Norgiolini<sup>2</sup>, Paola Del Sindaco<sup>1</sup>

<sup>1</sup>Diabetes Clinic - USL Umbria 1 – Perugia Territorial health structure, Italy, <sup>2</sup>Diabetes Clinic - USL Umbria 1 – Città di Castello Hospital, Italy, <sup>3</sup>Diabetes Clinic - USL Umbria 1 – Castiglione del Lago Hospital District, Italy.

Corresponding author

Chiara Di Loreto, MD

Diabetes Clinic - USL Umbria 1 – Perugia Territorial health structure, Italy

[chiara.diloreto@uslumbria1.it](mailto:chiara.diloreto@uslumbria1.it)

**Supplementary table 1:** data availability for each end-point at each visit

<b>Visit</b>	<b>T0</b>	<b>T6</b>	<b>T12</b>
<b>Study end-point</b>	<b>N</b>	<b>N</b>	<b>N</b>
HbA1c	211	156	67
Waist circumference	120	101	40
Weight	203	150	62
BMI	202	148	59
Systolic blood pressure	141	35	22
Diastolic blood pressure	141	34	22
Total cholesterol	174	96	46
Triglycerides	172	95	46
HDL- cholesterol	170	92	46
LDL- cholesterol	166	83	44
Creatinine	185	97	52

eGFR	185	97	52
Albuminuria	126	66	33
Semaglutide dose	216	172	70